FitLife Brands, Inc. — Form 10-Q Summary
Business Context and Reporting Period
FitLife Brands, Inc. develops and markets nutritional supplements under brands including NDS, PMD, SirenLabs, CoreActive, and Metis Nutrition. Products are sold primarily through GNC franchise locations and, for certain brands, corporate GNC stores. The company filed this unaudited quarterly report for the three and nine months ended September 30, 2015. The company had 10,358,222 common shares outstanding as of November 10, 2015.
The iSatori merger closed on September 30, 2015 and became effective October 1, 2015. Accordingly, iSatori’s operating results are not included in the reported September 30, 2015 periods. FitLife expected to issue approximately 2.3 million shares to iSatori shareholders.
Financial Results and Key Metrics
| Metric | Three Months Ended September 30, 2015 | Three Months Ended September 30, 2014 | Nine Months Ended September 30, 2015 | Nine Months Ended September 30, 2014 |
|---|---|---|---|---|
| Revenue | $6.271 million | $5.492 million | $15.140 million | $17.812 million |
| Gross profit | $2.612 million | $1.846 million | $6.124 million | $6.451 million |
| Gross margin | 41.7% | 33.6% | 40.5% | 36.2% |
| Operating income | $443,245 | $640,369 | $714,806 | $2.384 million |
| Operating margin | 7.1% | 11.7% | 4.7% | 13.4% |
| Net income | $383,258 | $564,079 | $584,533 | $2.183 million |
| Net margin | 6.1% | 10.3% | 3.9% | 12.3% |
| Diluted EPS | $0.04 | $0.07 | $0.07 | $0.25 |
Third-quarter revenue increased 14.2% year over year, while nine-month revenue declined 15.0%. Gross profit increased 41.5% in the quarter despite relatively flat cost of goods sold, reflecting improved raw-material pricing, volume discounts, and cost controls. Nine-month gross profit declined 5.1% because of lower sales volume.
Cash and cash equivalents were $3.055 million at September 30, 2015, compared with $4.354 million at December 31, 2014. Current assets were $11.235 million and current liabilities were $3.821 million, representing current assets of approximately 2.9 times current liabilities. Accounts receivable increased to $4.839 million from $1.686 million, principally because of the transition to GNC’s centralized distribution platform. Inventory declined to $1.670 million from $2.285 million.
Total debt was $2.005 million, consisting of a $437,089 revolving credit balance and a $1.568 million term loan. The current portion of debt was $957,976, and long-term debt was $1.047 million. The revolving line matures May 15, 2016, while the term loan matures August 15, 2018.
Operating activities used $518,159 of cash during the first nine months of 2015, compared with $630,310 provided in the prior-year period. Investing activities used $402,315, primarily reflecting $398,209 of common-stock repurchases. Financing activities used $378,561 for term-loan repayments. Cash declined by $1.299 million during the period.
Material Changes Versus the Prior Comparable Period
- Third-quarter revenue rose $778,190, or 14.2%, driven by stronger retail unit movement, approximately 20 new products introduced at the GNC convention, and the Metis Nutrition rollout.
- Nine-month revenue fell $2.672 million, or 15.0%, largely because the 2014 transition to GNC’s centralized distribution platform accelerated sales into the first half of 2014.
- Third-quarter general and administrative expense increased 65.2% to $854,729, including $250,594 of nonrecurring merger costs. Nine-month expense increased to $2.470 million, including $502,432 of merger-related costs.
- Selling and marketing expense increased 99.3% in the quarter and 55.1% year to date. The increases included $319,337 of product rebates related to the 2015 GNC convention, $127,620 for the JXT5 launch, and costs for three new employees.
- Quarterly operating income declined 30.8% and nine-month operating income declined 70.0%, while net income declined 32.1% and 73.2%, respectively.
- The company repurchased 46,387 shares during the quarter for $73,521. As of November 10, 2015, cumulative repurchases totaled 206,187 shares at an average price of $1.93 per share.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
Management stated that existing cash and anticipated operating cash flow were expected to provide liquidity for the next 12 months, although operating cash flow was negative through the first nine months. Management expected prior backlog and supply disruptions to be largely resolved and viewed them as nonrecurring. It also expected the GNC pricing transition to cease affecting period comparisons after 2015.
Management anticipated future growth from additional products, expansion of Metis Nutrition in corporate GNC stores, the addition of iSatori brands, broader store distribution, and international expansion. It also expected selling and marketing expense to grow at a lower rate in subsequent periods and general and administrative expense as a percentage of revenue to decline as iSatori operations were integrated. No specific quantitative revenue or earnings guidance was provided.
Key risks include dependence on GNC and other key customers, competition, market demand, product performance, supplier relationships, personnel retention, accounting changes, and execution of the iSatori integration. The company specifically warned that the acquisition may not achieve expected returns or cost savings and could reduce margins.
The company disclosed a Proposition 65 notice concerning alleged product-labeling violations; no lawsuit was filed during the notice period, and potential exposure could not be reasonably estimated. A separate lawsuit involving products containing Testofen was stayed pending resolution of an appeal in a related matter. No material loss accrual was disclosed for these matters.
The company reported approximately $18.779 million of federal net operating loss carryforwards, with a substantial valuation allowance. Utilization may be limited by Section 382 following changes in ownership, including the iSatori transaction. Management reported effective disclosure controls and internal control over financial reporting as of September 30, 2015.
Important Facts for Investors to Verify
- Confirm the final accounting for the iSatori merger, including the approximately 2.3 million shares issued, assumed debt, purchase price allocation, goodwill, and any subsequent impairment charges.
- Assess whether the company’s negative operating cash flow and increased accounts receivable reflect temporary GNC transition effects or continuing working-capital pressure.
- Review GNC customer concentration, pricing discounts, rebates, distribution terms, and the sustainability of the improved gross margin.
- Evaluate the integration costs, expected synergies, and potential dilution from iSatori shares, options, warrants, and other equity awards.
- Monitor debt maturities, borrowing-base availability under the revolving line, and the company’s ability to fund operations while repaying debt.
- Review the status and potential financial exposure of the Proposition 65 matter and the Testofen litigation.
- Verify the realizability and potential Section 382 limitations of the company’s deferred tax assets and net operating loss carryforwards.